Navigation Links
Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
Date:6/3/2008

Dr. Kenneth Kornman to Discuss Periodontal Inflammation and

Gene-Environment Interactions

WALTHAM, Mass., June 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), announced today that Dr. Kenneth Kornman, Chief Scientific Officer, will present at the 13th International Conference on Periodontal Research (ICPR) on June 6, 2008 in Ljubljana, Slovenia on the genetic and environmental factors that control inflammation differences among individuals. The ICPR meeting has been held approximately every three years since 1969 to bring together the world's leaders in periodontal research to reassess the current knowledge in the field and to identify new research direction, to improve the diagnosis, prevention, and treatment of periodontal diseases.

Periodontitis is a bacterially-induced chronic inflammatory disease that causes destruction of bone and other tissues that support the teeth. Severe periodontitis, that usually leads to loss of multiple teeth, is found in approximately 8-13 percent of the adult population. The presence and severity of periodontitis have been associated with an increased risk for other important inflammatory conditions, including pre-term births, cardiovascular disease, rheumatoid arthritis, and certain cancers.

WHO: Dr. Kenneth Kornman, Chief Scientific Officer of Interleukin

Genetics

WHERE: 13th International Conference on Periodontal Research (ICPR) in

Ljubljana, Slovenia

WHEN: Friday, June 6, 2008 at 9:45-10:30 GMT

WHAT: Approximately 30-60 percent of the severity of periodontal disease

is determined by genetics. Interleukin Genetics developed and

markets the PST(R) genetic test to help identify individuals at

increased risk for severe periodontal disease and complications

from dental implants. This test helps dentists guide the

management of their patients' periodontal disease to avoid

complications of severe periodontitis.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
2. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
4. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
5. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
6. Interleukin Genetics Retains Top Life Science Communications Firms
7. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
8. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
9. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. Interleukin Genetics Announces Management and Board Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... it will be hosting a Webinar titled, “Pathology is going digital. Is your ... on digital pathology adoption best practices and how Proscia improves lab economics and ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):